Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16352214 | 0.90 | NPC1 (0.55) | LCKKMT2ASMN1; SMN2KDM4EPKM | |
| SCHEMBL1970837 | 0.87 | LCK (0.54) | LCKMEN1KMT2ASMN1; SMN2PKM | |
| SCHEMBL1970914 | 0.85 | ALDH1A1 (0.55) | LCKKMT2AMAPTSMN1; SMN2KDM4E | |
| SCHEMBL1972073 | 0.85 | GRM5 (0.52) | LCKMEN1KMT2AKDM4EHDAC6 | |
| SCHEMBL16318598 | 0.84 | HDAC6 (0.48) | LCKMAPTHDAC6NPC1RAB9A | |
| SCHEMBL1972207 | 0.83 | PTGES (0.51) | LCK | |
| SCHEMBL1975476 | 0.83 | HDAC6 (0.48) | LCKHDAC6NPC1RAB9ANAMPT | |
| SCHEMBL16318704 | 0.83 | RAB9A (0.55) | MEN1KMT2AMAPTSMN1; SMN2PKM | |
| SCHEMBL1968998 | 0.82 | HDAC6 (0.65) | LCKMEN1KMT2AKDM4EHDAC6 | |
| SCHEMBL1971451 | 0.82 | HDAC6 (0.48) | LCKHDAC6NPC1RAB9ANAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2334652-A1 | 1H-BENZ IMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | Boehringer Ingelheim International GmbH (DE) | 2011-06-22 | — | — | EP | claimed |
| US-8916599-B2 | 1H-benz imidazole-5-carboxamides as anti-inflammatory agents | OREXO AB (SE) | 2014-12-23 | — | — | US | disclosed |
| US-8916599-B2 | 1H-benz imidazole-5-carboxamides as anti-inflammatory agents | OREXO AB (SE) | 2014-12-23 | — | — | US | disclosed |
| US-20110312935-A1 | 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| US-20110312935-A1 | 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
| WO-2010034796-A1 | 1H-BENZ IMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312935-A1 | 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents | MAPRE2, MAPRE1, H1-4 | LCK 1306/4885MEN1 2080/4885KMT2A 1047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.